Stepan Q3 2026 Earnings: Surfactants Drive 18% Adjusted EBITDA Growth

Stepan Company (NYSE: SCL) reported Q3 2026 net sales of $692.2 million, up 17% from $590.3 million a year earlier, while GAAP diluted EPS increased to $0.78 from $0.47. Adjusted EBITDA rose 18% to $66.3 million as Surfactant volume growth and margin recovery outweighed higher corporate costs; operating cash flow was $29.3 million, but working-capital requirements held free cash flow to $8.2 million.

Core Financial Results

Most of the revenue increase came from selling price and mix, which contributed 13 percentage points of growth. Reported volume added 3 points and foreign-currency translation added 1 point, while organic sales volume increased 7%.

Gross profit grew faster than revenue, lifting the calculated gross margin by approximately 0.6 percentage points. Operating income increased 19%, and a lower tax provision helped net income grow faster than operating profit. Adjusted results exclude restructuring, environmental remediation, and deferred-compensation items.

Free cash flow is a non-GAAP measure calculated as operating cash flow less $21.1 million of capital expenditures during the quarter.

Business and Segment Performance

All three segments increased quarterly sales and adjusted EBITDA, but Surfactants generated the largest earnings improvement. Polymers recorded the fastest sales growth, although that increase was driven mainly by raw-material cost pass-through rather than volume.

Surfactant selling prices increased 10%, primarily reflecting raw-material pass-through and other pricing actions. Global volume rose 3% and organic volume increased 8%. Double-digit growth in Consumer Products, Construction & Industrial, Oilfield, and the Tier 2/3 customer base was partly offset by weaker Crop Productivity demand. Volume growth and margin recovery drove the segment’s $10.2 million adjusted EBITDA increase.

Polymer pricing rose 22%, while volume increased 3%. North American volume grew at a double-digit rate, including significant Spray Foam growth, but Europe and Asia declined. Higher volume more than offset costs from the regulatory maintenance turnaround at Stepan’s German site, resulting in only a 4% adjusted EBITDA increase despite 24% sales growth.

Specialty Products volume increased 20%, supported by the medium-chain triglycerides product line. Less favorable product mix limited adjusted EBITDA growth to 5%, below the segment’s volume and revenue growth rates.

Profitability, Cash Flow, and Balance Sheet

Reported corporate expenses increased 49% to $26.2 million. The total included a $5.6 million pre-tax Project Catalyst restructuring charge and $3.1 million of environmental remediation expense, primarily reflecting a reserve adjustment for the Maywood, New Jersey site. Excluding specified adjustments, corporate expenses rose 6% to $17.5 million, mainly because of higher incentive-based compensation.

The quarterly Project Catalyst charge related to an organizational redesign involving approximately 100 salaried position reductions, or 7% of global salaried headcount. For the first nine months of 2026, restructuring charges totaled $76.1 million before tax, with an approximately $12.8 million year-to-date cash impact.

Working capital was the main constraint on cash generation. Net receivables, inventories, and accounts payable produced a combined working-capital balance of $526.9 million at September 30, up approximately $31.8 million from June 30. Receivables and inventories increased while accounts payable declined, absorbing cash during the quarter.

Total debt decreased by $13.3 million sequentially to $634.1 million, but cash fell by $15.6 million to $98.1 million. Consequently, net debt edged up by $2.3 million to $536.0 million, and the net debt ratio remained unchanged at 31%. After quarter-end, Stepan completed a $28.5 million land sale near its Millsdale site in October and said the full proceeds would be used to reduce debt.

Surfactants Supplied the EBITDA Gain, While Working Capital Absorbed Cash

Surfactant adjusted EBITDA increased by $10.2 million, slightly more than the company’s consolidated adjusted EBITDA increase of $10.1 million. This indicates that Surfactant volume growth and margin recovery supplied essentially all of the net year-over-year improvement after changes in the other segments and unallocated corporate costs.

At the same time, the 17% revenue increase was largely price-led, and the calculated adjusted EBITDA margin remained broadly stable at approximately 9.6%. The increase in working capital also meant that improved earnings did not translate fully into free cash flow during the quarter.

Management Commentary

CEO Luis E. Rojo attributed the adjusted EBITDA growth to global volume gains, margin recovery, and Project Catalyst savings. Management highlighted broad Surfactant demand and North American Polymer growth while acknowledging continuing global economic uncertainty and supply-chain disruption.

For full-year 2026, management said it expects adjusted EBITDA growth, positive free cash flow, and continued balance-sheet deleveraging. Its stated priorities remain growth opportunities, productivity initiatives, cash interventions, and execution of Project Catalyst.

Recent Insider Transactions

The supplied insider data showed no purchase transactions and no sale transactions during the previous six months, with total insider holdings of approximately 1.32 million shares. Among the latest records with complete transaction details, seven directors received stock awards and one officer completed a derivative-security exercise conversion; all were reported as direct ownership transactions.

Two later direct-ownership records for CFO Ruben Dario Velasquez and General Counsel Shawn G. Lisle did not include transaction or value details in the supplied data, so they are not characterized as purchases or sales.

Risks Investors Should Watch

• Raw-material and pricing exposure: Thirteen percentage points of quarterly revenue growth came from price and mix, largely reflecting raw-material cost pass-through. Continued cost volatility could affect the pace of margin recovery.
• Uneven demand across markets and regions: Lower Crop Productivity demand offset part of Surfactant growth, while Polymer volume declined in Europe and Asia despite strength in North America.
• Working-capital pressure: Rising receivables and inventories constrained free cash flow and contributed to a small sequential increase in net debt despite lower total debt.
• Project Catalyst execution: The program has produced substantial restructuring charges and workforce reductions. Future benefits depend on realizing the planned savings and efficiencies without material operating disruption.

Summary

Stepan’s Q3 2026 results showed better earnings across all three segments, led by Surfactant volume growth and margin recovery. Pricing actions drove most of the revenue increase, while higher working-capital requirements limited cash conversion. The main issues to monitor are whether organic volume growth remains broad, working capital normalizes, Project Catalyst savings continue, and the company converts its earnings improvement into positive free cash flow and lower leverage.